|
15 Aug 2023
Rameda Reports its 2Q23 Results
|
Q2 |
2023 |
|
|
01 Jun 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic products
|
Q2 |
2023 |
|
|
15 May 2023
Rameda Reports its 1Q23 Results
|
Q1 |
2023 |
|
|
07 Mar 2023
Rameda Reports its FY22 Results
|
Q4 |
2022 |
|
|
20 Dec 2022
Rameda acquires exclusive rights for the distribution and marketing of “Physiomer” in Egypt
|
Q4 |
2022 |
|
|
15 Nov 2022
Rameda Reports its 3Q22 Results
|
Q3 |
2022 |
|
|
21 Aug 2022
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. inaugurates a new high-precision water treatment station
|
Q3 |
2022 |
|
|
20 Jun 2022
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. joins the UN Global Compact, the world’s largest corporate sustainability initiative.
|
Q2 |
2022 |
|
|
15 Jun 2022
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires a fast-growing anticonvulsant which grew at 2019-21 CAGR of 226%
|
Q2 |
2022 |
|
|
23 May 2022
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires fast-growing molecule with an established market presence
|
Q2 |
2022 |
|
|
17 May 2022
Rameda Partners with IFC to Green its Operations in Egypt
|
Q2 |
2022 |
|
|
12 May 2022
Rameda Reports its 1Q22 Results
|
Q1 |
2022 |
|
|
07 Mar 2022
Equinox Pharma Holding Limited (Equinox), alongside other investors, further increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
|
Q1 |
2022 |
|
|
17 Jan 2022
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. commences the production of antiviral COVID-19 treatment, Molnupiravir Rameda
|
Q1 |
2022 |
|
|
24 Feb 2022
Rameda Reports its FY21 Results
|
Q4 |
2021 |
|
|
15 Nov 2021
Rameda Reports its 3Q21 Results
|
Q3 |
2021 |
|
|
28 Jul 2021
Equinox Pharma Holding Limited (Equinox) increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
|
Q3 |
2021 |
|
|
15 Jul 2021
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires a sizeable molecule in a fast-growing therapeutic area
|
Q3 |
2021 |
|
|
09 Aug 2021
Rameda Reports its 2Q21 Results
|
Q2 |
2021 |
|
|
06 May 2021
Rameda Reports its 1Q21 Results
|
Q1 |
2021 |
|
|
27 Jan 2021
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.’s Chief Executive Officer, Dr. Amr Morsy, recognized among the top 100 Arabian CEOs of 2020
|
Q1 |
2021 |
|
|
02 Mar 2021
Rameda Reports its FY20 Results
|
Q4 |
2020 |
|
|
10 Nov 2020
Rameda Reports its 3Q20 Results
|
Q3 |
2020 |
|
|
20 Jul 2020
Rameda notified of Anviziram, Remdesivir-Rameda vial prices by Egyptian Drug Authority, on track to market first Remdesivir-Rameda production in September 2020
|
Q3 |
2020 |
|
|
16 Aug 2020
Rameda Reports its 2Q20 Results
|
Q2 |
2020 |
|
|
22 Jun 2020
Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir
|
Q2 |
2020 |
|
|
28 Apr 2020
Rameda issues statement regarding the "Stay Home to Protect your Family and Community" initiative
|
Q2 |
2020 |
|
|
28 Apr 2020
Rameda values the role played by the Egyptian Pharmacists Syndicate and Pharmacies in serving patients across Egypt
|
Q2 |
2020 |
|
|
26 Apr 2020
Rameda launches initiative for the complementary dispensary and home delivery of medication at no cost, underlining its dedication to ensuring the healthcare and safety of some of Egypt’s most immune-compromised patient populations amid the COVID-19 pandemic
|
Q2 |
2020 |
|
|
17 May 2020
Rameda Reports its 1Q20 Results
|
Q1 |
2020 |
|
|
01 Apr 2020
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Acquires A Large Generic Product in a Sizable and Fast-Growing Therapeutic Area
|
Q1 |
2020 |
|
|
18 Feb 2020
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Reports double-digit topline growth in FY19 and major facility upgrades & expansions completed during the year
|
Q4 |
2019 |
|
|
26 Jan 2020
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Announced Indicative Results for FY2019
|
Q4 |
2019 |
|
|
11 Dec 2019
Rameda shares begin trading on Egyptian Exchange
|
Q4 |
2019 |
|
|
27 Nov 2019
Rameda announces the fixed offer price of its IPO on EGX
|
Q4 |
2019 |
|
|
30 Oct 2019
Rameda announces its intention to float on the Egyptian Exchange
|
Q4 |
2019 |
|
|
04 Dec 2019
Rameda Reports its 3Q19 Results
|
Q3 |
2019 |
|
